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CASE REPORT
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emphasis on peri-operative logistics
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Abstract
To the best of our knowledge this is the ﬁrst case of this nature described in the literature. Sharing the authors experience
with this case, particularly the technical challenges and post-operative management may aid other physicians facing similar
scenarios. In this report, we describe a pancreaticoduodenectomy for pancreatic adenocarcinoma in a patient with a previous left ventricular assist device (LVAD). A multidisciplinary approach, particularly close involvement of the advanced heart
failure, mechanical heart and pancreas surgery teams was key to the success of this case. Major abdominal surgery in the
setting of previous LVAD should be considered carefully, however, the LVAD should not be generalized as an absolute
contraindication.

INTRODUCTION
Over 2500 continuous left ventricular assist devices (LVAD)
devices were implanted in United States in 2014 and over
20 000 have been implanted worldwide to date [1]. With the
increasing prevalence of ventricular assist devices, noncardiac surgeries for this patient population are becoming a
more frequently encountered clinical scenario. Patients with
adenocarcinoma of the head of the pancreas who undergo surgery and adjuvant therapy have a 5-year survival of approximately 20% [2]. Patients with adenocarcinoma of the pancreas
who are not surgical candidates and receive only chemotherapy with or without radiation have a median survival of ~7–10
months [3]. Clearly, surgery plays a critical role in the potential
survival of patients with adenocarcinoma of the pancreas.
Herein, we present a patient with an LVAD who was subsequently diagnosed with adenocarcinoma of the head of the
pancreas. After careful consideration of the overall prognosis

in this patient with this complex clinical presentation, we
elected to perform a pancreaticoduodenectomy.

CASE REPORT
A 66-year-old male with New York Heart Association (NYHA)
stage IV heart failure, severe aortic stenosis, severe aortic insufﬁciency and porcelain aorta underwent implantation of a
HeartMate II LVAD as destination therapy by the Cardiac
Transplant and Mechanical Heart Service at our institution on
October 26, 2013. Nine months later, routine laboratory follow
up done July 20, 2014 revealed an elevated total bilirubin of 6.3
(0.2–1.1 mg/dL). Abdominal ultrasound showed cholelithiasis
and intra- and extra-hepatic biliary ductal dilation. Abdominal
computed tomography (CT) was not able to delineate the distal
common bile duct or pancreas head area due to LVAD artifact
(Figs. 1a and b). At this point, the patient’s anticoagulation was
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Figure 2: ERCP images illustrate the common bile duct with distal stricture, partially obstructed by the LVAD.

Figure 1: (a) Cross sectional imaging as a pre-operative study to deﬁne the pancreatic anatomy is limited by the LVAD artifact. (b) Computed tomography
scout ﬁlm shows the location of the LVAD and LVAD driveline in the chest and
abdomen.

Figure 3: Endoscopic ultrasound images of the adenocarcinoma of the head of
the pancreas.

reversed and the patient underwent endoscopic retrograde cholangiopancreatography (ERCP). Fluoroscopy for the ERCP was
limited by the LVAD, however, a tight distal common bile duct
stricture of about 2 cm in length was noted (Fig. 2). ERCP was
followed immediately by endoscopic ultrasound (EUS) that
showed a 2.8 cm pancreatic head mass (Fig. 3). On EUS, the
mass was not abutting the portal vein, superior mesenteric
vein, superior mesenteric artery or celiac artery. Also, there
was no signiﬁcant lymphadenopathy per EUS. Fine needle
aspiration of the pancreatic head mass was consistent with
adenocarcinoma. Rest of the work-up included a chest-CT
which was negative for metastatic disease, CA19-9 was 27
(0–37 U/mL). The case was discussed at our multidisciplinary
liver and pancreas tumor board and after several care conferences with the family and involved providers, the decision
was made to proceed with a pancreaticoduodenectomy on
August 14, 2014.
Initial diagnostic laparoscopy was negative for metastatic
disease, and conﬁrmed expected adhesions to the LVAD Gortex
pouch that is fashioned from the diaphragm (Fig. 4). After conﬁrming the absence of metastatic disease, we then proceeded

LVAD Gortex pouch

Stomach

Figure 4: A pouch made of Gortex and secured to the inferior face of the diaphragm houses the LVAD and sits over the mid and upper quadrants of the
abdomen.

with a standard pancreaticoduodenectomy. We also had to do
a small segment side bite resection of the portal vein with primary repair due to suspected involvement. He tolerated the
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umbilicus. The driveline also loops across the abdomen and
exits in the left abdominal wall. The surgeon needs to be aware
of these factors and be ﬂexible with the location of the incision.

Retraction and exposure
Components of the inﬂow and outﬂow cannulas of the LVAD
are made of pliable materials, therefore continuous intraoperative ﬂow monitoring by a mechanical heart engineer is
required for these cases.

Linear ﬂow (HeartMate CF) and identiﬁcation of vascular
structures

Figure 5: Dotted line shows the subcutaneous location of the driveline (LVAD
power cord). A typical midline incision or subcostal incision was not feasible
due to the driveline trajectory.

procedure well and without any blood transfusions, estimated
blood loss was 200 mL. He was extubated at the end of the case
and was transferred to the Cardiac Intensive Care Unit for further care. A drain left around the hepatico and pancreatico
jejunal anastomosis was removed on post-operative Day #3
after checking the amylase level per our institutional protocol.
By post-operative Day #8 he was tolerating a regular soft diet
and having regular bowel function. He did not have any infectious or bleeding complications post-operatively. He stayed in
the hospital until post-operative Day #17 mainly for close management of his overall ﬂuid status and optimizing anticoagulation per the Mechanical Heart team. His ﬁnal pathology
showed a 3.0 cm, well differentiated tumor, without lymphovascular invasion, with peri-neural invasion, with three lymph
nodes positive by direct extension out of 17 total, surgical margins clear of cancer, Stage IIB, T3N1M0.
Approximately 6 weeks after surgery, he was started on
adjuvant chemotherapy with single agent Gemcitabine. He
completed total of 6 months of Gemcitabine without major side
effects.
At the time this report was drafted, the patient was 30 months
out from surgery with no evidence of recurrent disease.

DISCUSSION
Pancreatic cancer pre-operative imaging
Due to LVAD streaking artifact on CT, pre-operative good quality imaging of the pancreas was only possible with endoscopic
ultrasound.

Surgical challenges

Incision (presence of the LVAD driveline—Fig. 3)
Our incision had to be altered from our standard midline supraumbilical incision in order to avoid the driveline (Fig. 5). As
depicted in Figs 1a and b, the LVAD pump occupies a signiﬁcant
amount of the left abdominal wall from the costal margin to the

Identiﬁcation of the superior mesenteric artery, celiac artery,
hepatic artery, gastroduodenal artery or any arterial anatomic
variants (i.e. replace right hepatic artery) is key to the operation. In patients with previous LVAD the lack of arterial pulsatile ﬂow makes identiﬁcation of these structures by palpation
or Doppler not possible. Intra-operative ultrasound plays a bigger role for identiﬁcation of vascular structures.

Post-operative anticoagulation
LVAD patients are routinely kept anticoagulated with a target
INR (international normalized ratio) between 1.8 and 2.5. In our
case, the INR was corrected and the patient was kept on a heparin drip until two hours prior to surgery. Full dose intravenous heparin drip was started on post-operative Day 2 and
Coumadin was started on post-operative Day 3.

CONCLUSION
Close collaboration with the LVAD team is key to the successful
care of these patients. Based on our limited experience, currently at our institution previous history of LVAD is not an absolute contraindication for major abdominal oncologic surgery.
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